| Position | Action |
|---|---|
| Current position | Maintain no change to sizing |
| Daily close above $393 50 SMA on volume ≥ 20-day average | Scale in (do not add aggressively) |
| Break below $328.57 panic low | Force re-evaluation |
ISRG is a high-quality compounder in a tactical pullback, with reaccelerating fundamentals, a widening competitive moat, and a fortress balance sheet that justifies the premium multiple and makes any weakness an accumulation opportunity.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 393.18 | bearish |
| close_200_sma | 480.18 | bearish |
| close_10_ema | 368.19 | bullish |
| macd | -7.17 | bullish |
| macdh | +4.70 | bullish |
| rsi | 51.32 | neutral |
| atr | 13.55 | neutral |
| vwma | 356.60 | bearish |
Support: 356.6 · 332.02 · 328.57 | Resistance: 393.18 · 405.64 · 480.18
ISRG staged a tactical bounce from its $328.57 intraday panic low (July 23, 2026) to $378.81, recovering ~23% from peak-to-trough decline. Short-term momentum has improved — MACD histogram flipped positive (+4.70, expanding over 6 sessions), RSI recovered from oversold ~29 to 51.32, and price reclaimed the 10 EMA (368.19) for the first time in ~4 weeks. However, structural indicators remain bearish: price is 3.6% below the declining 50 SMA (393.18) and ~21% below the 200 SMA (480.18), with the VWMA (356.60) declining and the bounce occurring on sub-average volume. The transaction proposal is HOLD — traders with positions should be tactical with tight stops at 1× ATR (~$365) or 2× ATR (~$352), taking partial profits at the 50 SMA; traders without exposure should await a confirmed re-entry on daily close above 393 on expanding volume.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Hold ISRG: keep the business, respect the tape, wait for confirmation above $393
Hold is the synthesis of bull and bear correctness: keep the business, respect the tape, wait for confirmation. A 23% drawdown on an accelerating compounder with fortress balance sheet does not warrant selling, but adding aggressively into declining moving averages with beta 1.46 into a binary CPI print fights the tape without confirmed edge. Preserve current exposure, keep powder dry for either trend reversal confirmation at $393 or a deeper flush toward $300-320 that produces a higher-quality basing structure.
When: Flush toward $300-320 with volume drying up
Then: Higher-quality basing structure for potential re-entry
· concedes: Domestic procedure volumes ran a touch soft on tough comps — a near-term mix issue, not structural break; 43.5x trailing P/E is elevated (though forward P/E of 31.4x normalizes the PEG to ~1.2); One quarter of softer domestic volumes doesn't undo reaccelerating growth — watch Q3 for stabilization; PEG of 1.83 on trailing basis is rich, though forward metrics are more relevant; 200-day moving average is $101 above current price — structural overhead resistance exists
A great business at a bad price — the stock is expensive until it isn't, and the current setup features technical deterioration, decelerating growth, finite buyback support, inventory accumulation, and macro headwinds that collectively justify UNDERWEIGHT rather than the quality-at-any-price framing the bull uses.
· concedes: ISRG is a great company with a genuine moat, zero debt, strong cash flow, and a long-term runway; The balance sheet and business quality are not in dispute; The drawdown from $432.83 to $378.81 represents genuine value emergence IF the technical and fundamental deterioration proves temporary; A higher high and higher low on the daily chart after a structural base would change the entry picture
→ vs conservative: The 50 SMA at $393 is declining due to the recent crash; waiting for clean reclaim means buying at $405-$420 and giving up half the discount. This is performance anxiety masquerading as prudence.
→ vs neutral: Sub-average volume on the bounce is a concern for momentum trades, but this is a quality compounder at a discount, not a momentum trade. The right question is whether to own this at 31x forward P/E with 20% growth or pay 50% more later.
Market Cap
$135.7B
52W High
$603.88
52W Low
$328.57
50-DMA
$397.92
200-DMA
$481.57
Beta
1.46
P/E (TTM)
43.5x
Forward P/E
31.4x
PEG Ratio
1.83
P/B
7.38x
EV/EBITDA
~32x
Revenue YoY (Q2 2026)
+18.5%
EPS YoY (Q2 2026)
+26.5%
Revenue YoY (2025)
+20.5%
Revenue (TTM)
$11,034M
Gross Margin (TTM)
66.7%
Operating Margin (TTM)
33.6%
Net Margin (TTM)
28.4%
ROE
17.4%
ROA
10.5%
Cash + ST Investments
$5.22B
Total Debt
$0
Current Ratio
4.96x
Stockholders' Equity
$18.17B
TTM FCF
$2.62B
FCF Margin
23.7%
1H 2026 Buybacks
$1.44B
Q1 2026 Buybacks
$1,123.2M
Shares Outstanding
~353.9M
Diluted EPS (TTM)
$8.71
Q2 2026 Revenue
$2,892.3M
Q2 2026 Operating Income
$971.9M
Q2 2026 Net Income
$818.1M
Q2 2026 FCF
$948.4M
Inventory
$2,029M
Net PPE
$5,552M
2025 Net Income
$2,856M
2025 Diluted EPS
$7.87
Strengths
Concerns
Intuitive Surgical is a structurally excellent compounder in robotic-assisted minimally invasive surgery, featuring a razor-and-blade business model (system sales + recurring instruments/consumables + services) that generated $11B TTM revenue with accelerating 20%+ growth. The company has achieved pristine financial quality with 33.6% operating margins, $2.62B annual FCF, zero debt, and $5.2B cash, while returning $1.44B to shareholders via buybacks in just 1H 2026. Despite premium multiples (43.5x P/E, 7.4x P/B) and above-market beta (1.46), the stock presents a high-quality opportunity for investors seeking an entry near $380 or above the 200-DMA technical level.